专利号:US-10005720-B2 优先权日:2013-04-05 标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same 发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L 权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL 摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.
专利号:US-8420850-B2 优先权日:2010-05-14 标 题:Compounds for the synthesis of biostable polyurethane, polyurea or polyurea urethane polymers 发明人:DUOCASTELLA CODINA LLUIS; MOLINA MARIA; ARAD OFIR; BORRELL BILBAO JOSE IGNACIO; GARCIA DAVID SANCHEZ; PETTERSON SALOM SOFIA HENRIETTE 权利人:DUOCASTELLA CODINA LLUIS; MOLINA MARIA; ARAD OFIR; BORRELL BILBAO JOSE IGNACIO; GARCIA DAVID SANCHEZ; PETTERSON SALOM SOFIA HENRIETTE; IBERHOSPITEX SA 摘要:The invention comprises compounds which are derived from a drug or a substance with therapeutic properties, and useful as reagents for the synthesis of biostable polymers including said drug in their backbone, namely polyurethanes, polyureas or polyurea urethanes that are biocompatible and biostable. The invention also comprises the processes for preparing the compounds and the polymers, and to the use of these polymers for the manufacture of medical devices.
专利号:US-6686497-B1 优先权日:1999-11-16 标题:Synthesis of 3-ethoxy-4-ethoxycarbonyl phenyl acetic acid, a key acid synthon of repaglinide 发明人:SALMAN MOHAMMAD; BABU J SURESH; RAY PURNA C; BISWAS SUJAY; KUMAR NARESH 权利人:RANBAXY LAB LTD 摘要:The present invention relates to a new and industrially advantageous process for the preparation of 3-ethoxy-4-ethoxy-carbonyl-phenyl acetic acid. This compound is a key intermediate for the synthesis of Repaglinide, an oral hypoglycemic agent.
专利号:WO-2024123268-A1 优先权日:2022-12-09 标 题 :Production of silver nanoparticles by green synthesis using hazelnut husk extract 发明人:AKDOGAN OZAN; GUNDUZ AKDOGAN NILAY; SIVRI DAMLA; KUREL ALI 权利人:BAHCESEHIR UNIV; PIRI REIS UNIV 摘要:The invention relates to synthesis of nanoparticles from hazelnut husk extract by green synthesis with high efficiency. Use of chemical is limited in the present invention and therefore the synthesis of nanoparticles is provided by green chemistry in the present invention. Said hazelnut may be Corylus and said hazelnut husk may be cob or shell of the hazelnut. In an embodiment of the invention said Corylus may be Colyrus colurna, Corylus americana Corylus avellana, Corylus avellana var. Avellana, Corylus avellana var. Pontica, Corylus chinensis, Corylus colchica, Corylus × colurnoides, Corylus cornuta, Corylus cornuta ssp. californica, Corylus cornuta ssp. cornuta, Corylus fargesii, Corylus ferox, Corylus ferox var. ferox, Corylus ferox var. thibetica, Corylus heterophylla, Corylus heterophylla var. heterophylla, Corylus heterophylla var. sutchuensis, Corylus jacquemontii, Corylus maxima, Corylus potaninii, Corylus sieboldiana, Corylus sieboldiana var. mandshurica, Corylus sieboldiana var. sieboldiana, Corylus wangii, Corylus wulingensis or Corylus yunnanensis.
专利号:US-2008287407-A1 优先权日:2003-12-10 标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use 发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI 权利人:NITROMED INC 摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.
专利号:US-2009156465-A1 优先权日:2005-12-30 标题:Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors 发明人:SATTIGERI JITENDRA A; AHMED SHAHADAT; ANDAPPAN MURUGAIAH M S; SETHI SACHIN; SHARMA LALIMA; PAL CHANCHAL KUMAR; KANDALKAR SACHIN RAMESH; MAHAJAN DIPAK C; KISHORE KAUSHAL; BHATIA SUMATI; GADHAVE ANIL G; BANSAL VINAY S; DAVIS JOSEPH ALEXANAND 权利人:SATTIGERI JITENDRA A; AHMED SHAHADAT; ANDAPPAN MURUGAIAH M S; SETHI SACHIN; SHARMA LALIMA; PAL CHANCHAL KUMAR; KANDALKAR SACHIN RAMESH; MAHAJAN DIPAK C; KISHORE KAUSHAL; BHATIA SUMATI; GADHAVE ANIL G; BANSAL VINAY S; DAVIS JOSEPH ALEXANAND 摘要:The present invention relates to β-amino acid derivatives as dipeptidyl peptidase-IV inhibitors and the processes for the synthesis of the same. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating diabetes, especially type 2 diabetes, as well as prediabetes, diabetic dyslipidemia, metabolic acidosis, ketosis, satiety disorders, and obesity. These inhibitors can also be used to treat conditions manifested by a variety of metabolic, neurological, anti-inflammatory, and autoimmune disorders like inflammatory disease, multiple sclerosis, rheumatoid arthritis; viral, cancer and gastrointestinal disorders. The compounds of this invention can also be used for treatment of infertility arising due to polycystic ovary syndrome.
1: Wang Q, Rao HY, Yu N, Gao SQ, Wei L. [Comorbidities and concomitant medication use in adult patients with chronic hepatitis C: a descriptive epidemiological analysis]. Zhonghua Gan Zang Bing Za Zhi. 2018 Mar 20;26(3):225-232. doi: 10.3760/cma.j.issn.1007-3418.2018.03.011. Chinese. doi: 10.1016/j.biopha.2017.11.073. Epub 2017 Nov 20. doi: 10.1002/ddr.21426. Epub 2018 Apr 16. doi: 10.5414/CP203199. doi: 10.1016/j.ejphar.2018.03.025. Epub 2018 Mar 16. doi: 10.1186/s13041-018-0359-6. 12: Rodriguez-Poncelas A, Barrot-de la-Puente J, Coll de Tuero G, López-Arpí C, Vlacho B, Lopéz-Simarro F, Mundet Tudurí X, Franch-Nadal J. Glycaemic control and treatment of type 2 diabetes in adults aged 75 years or older. Int J Clin Pract. 2018 Mar;72(3):e13075. doi: 10.1111/ijcp.13075. Epub 2018 Mar 7. doi: 10.1124/dmd.117.079590. Epub 2018 Feb 8. doi: 10.1111/bcp.13533. Epub 2018 Mar 6. 16: Abo-Elseoud WS, Hassan ML, Sabaa MW, Basha M, Hassan EA, Fadel SM. Chitosan nanoparticles/cellulose nanocrystals nanocomposites as a carrier system for the controlled release of repaglinide. Int J Biol Macromol. 2018 May;111:604-613. doi: 10.1016/j.ijbiomac.2018.01.044. Epub 2018 Jan 9. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018 Feb;6(2):114-121. doi: 10.1016/S2213-8587(17)30400-X. Epub 2017 Dec 5. doi: 10.1002/pds.4337. Epub 2017 Nov 6.
合成参考文献
参考文献:10.4196/kjpp.2008.12.1.7 摘要:Park JK, Kim SP, Song DK. Ameliorating effects of sulfonylurea drugs on insulin resistance in Otsuka long-evans Tokushima Fatty rats. Korean J Physiol Pharmacol. 2008 Feb;12(1):7–12. 参考文献:10.2147/dmso.s19027 摘要:Pham PT, Pham PM, Pham SV, Pham PA, Pham PC. New onset diabetes after transplantation (NODAT): an overview. Diabetes Metab Syndr Obes. 2011;4():175–86. 参考文献:10.1007/s00592-011-0312-y 摘要:Ekholm E, Shaat N, Holst JJ. Characterization of beta cell and incretin function in patients with MODY1 (HNF4A MODY) and MODY3 (HNF1A MODY) in a Swedish patient collection. Acta Diabetol. 2012 Oct;49(5):349–54. doi: 10.1007/s00592-011-0312-y. 参考文献:10.2174/1874357901105010080 摘要:D'Abramo CM, Archambault J. Small molecule inhibitors of human papillomavirus protein - protein interactions. Open Virol J. 2011;5():80–95. 参考文献:10.1007/s10354-011-0914-6 摘要:Lechleitner M. Oral antidiabetic drug therapy in type 2 diabetes mellitus - focus on elderly patients. Wien Med Wochenschr. 2011 Jun;161(11-12):297–9. doi: 10.1007/s10354-011-0914-6.